🔗 Share this article

While the United States proceeds with sweeping revisions to its immunization recommendations, one figure appears unexpectedly: Dr. Tracy Beth Høeg, an American of Danish descent physician and epidemiologist who first made her name by questioning Covid shots in the pandemic and has focused upon possible fatalities after COVID-19 vaccination in her recent time at the Food and Drug Administration.

Planned Shifts to Pediatric Vaccine Schedule

Public health authorities planned to announce radical changes to the pediatric vaccination calendar recently, aligning the US with Denmark’s vaccine program, according to reports – a substantial departure that would place the US out of alignment with much of the world with insufficient data for improved outcomes. This reveal has been delayed until the new year.

Instead of the director of the vaccine center, Høeg is listed to speak at the event. She was newly appointed temporary leader of the FDA’s drug evaluation center, the fifth individual to head the office this calendar year.

Consolidating Power at the Regulatory Body

Høeg's temporary position might represent a closer partnership between the drug and biologics divisions as Høeg and Dr. Prasad consolidate power at the regulatory agency – and it suggests a increased emphasis upon reevaluating long-standing vaccines at the FDA.

The new acting director has repeatedly called for ending specific childhood vaccine recommendations in the US in order to be more similar to the Danish model, a country with nationalized medicine and a citizenry about the population of the state of Wisconsin.

So far public appearances, she has kept her attention on vaccines – usually the domain of Dr. Prasad, head of the FDA’s vaccine center – as opposed to drug regulation.

Doubts Over Qualifications

Høeg has no apparent track record in medication creation, approval processes or management, which has been customary for previous heads of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a key advisor to the agency head and CBER since spring.

“She doesn’t seem to have the requisite experience” for leading the pharmaceutical oversight division, remarked Dr. Jonathan Howard. “She has not conducted a scientific study. She lacks experience in running a sizeable institution. She lacks background in drug approvals.”

Former commissioners of CBER would “grasp legal statutes and the underlying principles of drug development”, noted a former acting FDA commissioner. “Frankly, she lacks the type of experience that prior appointees who ran CBER have had.”

CDER has an vast workload at the agency, the former commissioner stated.

“The public just zeroes in on the new drug program, but the generic drug division approves a multitude of off-brand pharmaceuticals. There’s a biosimilars division, non-prescription drug unit and other areas, and each of these must be looked after,” she noted. “The thing you don’t keep your eye on, that is precisely what that I always told people is going to bite you.”

Furthermore, a significant administrative aspect to the job, which manages in excess of 5,000 personnel. “It is a enormous leadership role, if you do it right,” the former official said.

Response and Disputed Programs

In response to inquiries about Dr. Høeg's fitness for the role and whether this assignment signifies increased cooperation among FDA leaders on vaccines, a press secretary responded that the “questions rely on flawed premises”.

“Her experience matches the responsibilities of her role,” the official stated, pointing to the months Høeg spent counseling the FDA commissioner on “medication safety and regulatory science, including predictive safety algorithms and vaccine surveillance”.

As the temporary head, Høeg takes over the agency head's recently launched priority voucher program, a controversial expedited medication authorization process that allegedly concerned her former heads. “How are these drugs being picked for this expedited pathway? Who takes the choices?” Dr. Howard questioned. “There’s a lot of secrecy occurring at the agency right now.”

Overall, he said, “the agency appears to be shifting towards less stringent oversight of most medications, except for immunizations.”

Public Track Record on Vaccines

Concerning vaccines, Høeg has a more established, if concerning, history, some experts observe. She authored a research paper using non-validated crowd-sourced reports to estimate the incidence of heart inflammation following Covid vaccination. She counseled the Florida chief medical officer Joseph Ladapo, who allegedly have changed statistics to suggest Covid vaccines are riskier than they are.

Part of her “desired changes” for the new administration featured revising rules for novel immunizations and halting “non-essential” vaccines, she remarked post-election on a podcast. At the agency, Dr. Høeg has reportedly proposed preventing teenage boys from receiving Covid vaccines.

“She’s an thorough true believer who begins with her preconceived notions and works backwards to accommodate the evidence in a highly disingenuous, dishonest fashion,” Howard argued.

Gaining Influence and a “Campaign of Retribution”

Høeg became part of other contrarians, {like|